Show simple item record

dc.contributor.authorKrol, I
dc.contributor.authorCastro-Giner, F
dc.contributor.authorMaurer, M
dc.contributor.authorGkountela, S
dc.contributor.authorSzczerba, BM
dc.contributor.authorScherrer, R
dc.contributor.authorColeman, N
dc.contributor.authorCarreira, S
dc.contributor.authorBachmann, F
dc.contributor.authorAnderson, S
dc.contributor.authorEngelhardt, M
dc.contributor.authorLane, H
dc.contributor.authorEvans, TRJ
dc.contributor.authorPlummer, R
dc.contributor.authorKristeleit, R
dc.contributor.authorLopez, J
dc.contributor.authorAceto, N
dc.date.accessioned2018-11-14T09:45:05Z
dc.date.issued2018-08
dc.identifier.citationBritish journal of cancer, 2018, 119 (4), pp. 487 - 491
dc.identifier.issn0007-0920
dc.identifier.urihttps://repository.icr.ac.uk/handle/internal/2931
dc.identifier.eissn1532-1827
dc.identifier.doi10.1038/s41416-018-0186-7
dc.description.abstractHuman glioblastoma (GBM) is a highly aggressive, invasive and hypervascularised malignant brain cancer. Individual circulating tumour cells (CTCs) are sporadically found in GBM patients, yet it is unclear whether multicellular CTC clusters are generated in this disease and whether they can bypass the physical hurdle of the blood-brain barrier.  Here, we assessed CTC presence and composition at multiple time points in 13 patients with progressing GBM during an open-label phase 1/2a study with the microtubule inhibitor BAL101553. We observe CTC clusters ranging from 2 to 23 cells and present at multiple sampling time points in a GBM patient with pleomorphism and extensive necrosis, throughout disease progression. Exome sequencing of GBM CTC clusters highlights variants in 58 cancer-associated genes including ATM, PMS2, POLE, APC, XPO1, TFRC, JAK2, ERBB4 and ALK. Together, our findings represent the first evidence of the presence of CTC clusters in GBM.
dc.formatPrint-Electronic
dc.format.extent487 - 491
dc.languageeng
dc.language.isoeng
dc.rights.urihttps://creativecommons.org/licenses/by/4.0
dc.subjectAnimals
dc.subjectHumans
dc.subjectMice
dc.subjectGlioblastoma
dc.subjectBrain Neoplasms
dc.subjectDisease Progression
dc.subjectOxadiazoles
dc.subjectBenzimidazoles
dc.subjectCell Count
dc.subjectCluster Analysis
dc.subjectXenograft Model Antitumor Assays
dc.subjectMutation
dc.subjectFemale
dc.subjectMale
dc.subjectGene Regulatory Networks
dc.subjectNeoplastic Cells, Circulating
dc.subjectGenetic Variation
dc.subjectWhole Exome Sequencing
dc.titleDetection of circulating tumour cell clusters in human glioblastoma.
dc.typeJournal Article
dcterms.dateAccepted2018-06-25
rioxxterms.versionofrecord10.1038/s41416-018-0186-7
rioxxterms.licenseref.urihttps://creativecommons.org/licenses/by/4.0
rioxxterms.licenseref.startdate2018-08
rioxxterms.typeJournal Article/Review
dc.relation.isPartOfBritish journal of cancer
pubs.issue4
pubs.notesNot known
pubs.organisational-group/ICR
pubs.organisational-group/ICR/Primary Group
pubs.organisational-group/ICR/Primary Group/ICR Divisions
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Cancer Therapeutics
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Cancer Therapeutics/Cancer Biomarkers
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Cancer Therapeutics/Medicine (de Bono Prostate)
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Cancer Therapeutics/Molecular Addictions
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Clinical Studies
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Clinical Studies/Cancer Biomarkers
pubs.organisational-group/ICR/Students
pubs.organisational-group/ICR/Students/PhD and MPhil
pubs.organisational-group/ICR/Students/PhD and MPhil/16/17 Starting Cohort
pubs.organisational-group/ICR
pubs.organisational-group/ICR/Primary Group
pubs.organisational-group/ICR/Primary Group/ICR Divisions
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Cancer Therapeutics
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Cancer Therapeutics/Cancer Biomarkers
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Cancer Therapeutics/Medicine (de Bono Prostate)
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Cancer Therapeutics/Molecular Addictions
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Clinical Studies
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Clinical Studies/Cancer Biomarkers
pubs.organisational-group/ICR/Students
pubs.organisational-group/ICR/Students/PhD and MPhil
pubs.organisational-group/ICR/Students/PhD and MPhil/16/17 Starting Cohort
pubs.publication-statusPublished
pubs.volume119
pubs.embargo.termsNot known
icr.researchteamMedicine (de Bono Prostate)en_US
icr.researchteamMolecular Addictionsen_US
icr.researchteamCancer Biomarkersen_US
dc.contributor.icrauthorCarreira, Suzanneen
dc.contributor.icrauthorLopez, Juanitaen
dc.contributor.icrauthorColeman, Niamhen


Files in this item

Thumbnail

This item appears in the following collection(s)

Show simple item record

https://creativecommons.org/licenses/by/4.0
Except where otherwise noted, this item's license is described as https://creativecommons.org/licenses/by/4.0